Rhodiola Rosea Drug Interactions: MAOIs, Stimulants, and What NCCIH Documents
Rhodiola rosea is an adaptogenic herb used primarily for fatigue, stress, and cognitive performance. It has a longer and better-characterized safety record than many supplements in this category, but that doesn't mean it's interaction-free. Two areas warrant specific attention: its mild monoamine oxidase (MAO) inhibiting properties, which create a theoretical interaction with prescription antidepressants in the MAOI class, and its stimulant-like effect on dopamine and norepinephrine systems, which may be additive with stimulant medications. Understanding these mechanisms helps clarify which combinations to approach cautiously.
MAO inhibition: the antidepressant interaction
Monoamine oxidase is the enzyme responsible for breaking down serotonin, dopamine, and norepinephrine in the brain and elsewhere. Prescription MAOIs — phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan) — block this enzyme, allowing monoamines to accumulate. This is their therapeutic mechanism for treatment-resistant depression, but it also means that anything else with MAO-inhibiting activity adds to that effect.
Rhodiola extracts, particularly the compounds salidroside and the rosavins, have shown mild MAO-inhibiting activity in preclinical research. Whether this translates to clinically meaningful MAO inhibition in humans at typical supplemental doses is not established — the effect is substantially weaker than prescription MAOIs. But the combination with prescription MAOIs is still worth flagging: stacking a supplement with even mild MAO-inhibiting properties on top of a drug that already maximally suppresses MAO creates theoretical risk for excess monoamine accumulation, including serotonin.
Selective MAO-B inhibitors used in Parkinson's disease — selegiline (Emsam) and rasagiline (Azilect) — also carry this consideration, particularly because at higher doses they lose selectivity and begin inhibiting MAO-A as well, which governs serotonin metabolism. Linezolid, an antibiotic used for serious drug-resistant infections, has MAOI properties and the same concern applies despite its non-psychiatric indication. NCCIH notes that rhodiola may interact with drugs that affect monoamine oxidase systems.
The practical takeaway is not that rhodiola is dangerous for most people — it isn't — but that the specific combination with a prescription MAOI should prompt a conversation with the prescribing physician before proceeding.
Stimulant properties and additive cardiovascular effects
Rhodiola's adaptogenic effects appear to involve dopaminergic and noradrenergic neurotransmission — the same systems that prescription stimulants target more aggressively. This is part of why rhodiola is used for energy and cognitive performance: it increases monoamine availability through mechanisms distinct from reuptake inhibition but with overlapping outcomes.
Combined with prescription stimulants — methylphenidate (Ritalin, Concerta), amphetamines (Adderall, Vyvanse), modafinil (Provigil), or phentermine — the additive stimulation on dopamine and norepinephrine pathways may amplify cardiovascular effects: elevated heart rate, higher blood pressure, and in some cases increased anxiety or worsened insomnia. The effect is not equivalent to taking two doses of the stimulant — rhodiola's mechanism is indirect and adaptogenic — but for people who are already sensitive to cardiovascular side effects from their stimulant medication, adding rhodiola is not neutral.
High caffeine intake compounds this further. Many people using rhodiola for performance or cognitive enhancement are already using substantial caffeine. Triple stacking caffeine, a prescription stimulant, and rhodiola pushes on all the same systems, and the combined effect on heart rate and blood pressure deserves attention. NCCIH recommends caution when combining rhodiola with stimulant medications.
Blood pressure and diabetes context
Rhodiola has been studied for effects on stress-related cardiovascular parameters. Some research suggests it may modestly lower blood pressure in people with mild hypertension, which is relevant for anyone already on antihypertensive therapy — the additive hypotensive effect could produce symptomatic drops in blood pressure, particularly on standing (orthostatic hypotension). This interaction is less well-characterized than the MAO and stimulant interactions, but worth noting for people managing blood pressure with medication.
There is also preliminary evidence that rhodiola may have mild effects on glucose metabolism, though this is much less established than the MAO and stimulant interaction data. People managing blood sugar with medications should monitor for any unexpected changes if adding rhodiola.